METHODS IN CLINICAL CANCER RESEARCH

Educating early-career investigators in the best practices of clinical trial design

26 JUNE > 2 JULY 2020

eortc.org/mccr
# TABLE OF CONTENT

1. **INTRODUCTION**  
   - Page 3

2. **EDUCATIONAL FORMAT**  
   - Page 5

3. **FACTS & FIGURES**  
   - Page 6

4. **CORPORATE SUPPORT OPPORTUNITIES**  
   - Page 8

5. **BOOKING FORM**  
   - Page 9

6. **FELLOW TESTIMONIALS**  
   - Page 10
1. INTRODUCTION

The World Health Organisation estimates clinical shortages in 83 countries. With more trials being conducted globally, this shortage represents a set of challenges for clinical research. A review of literature shows that, despite advances in basic science and new preclinical agent development, there is a serious shortage of clinical investigators who have the pre-requisite knowledge to design and conduct effective clinical trials to match the attributes of these new agents. With the ever-increasing pace of technology and its implications in clinical trial design, the knowledge and number of tools that a clinical investigator needs to be able to utilise effectively continue to grow at a rapid rate.

THE MCCR WORKSHOP

The annual Methods in Clinical Cancer Research Workshop is a week-long course designed to educate and train early-career investigators in the best practices of clinical trial design and provide access to experienced clinical investigators from different institutions and countries with expertise across all areas of clinical research. The Workshop is organised by the European Organisation of Research and Treatment of Cancer (EORTC), European Society of Medical Oncology (ESMO), and American Association for Cancer Research (AACR) and has provided training to over 1600 investigators from all over the world since its inception in 1999.

The Workshop is offered to early-career investigators in all disciplines working the field of oncology who are nearing completion of their training or have recently begun their initial faculty positions and is designed to address the needs today, while maintaining flexibility to implement changes to train early-career investigators on how to conduct effective clinical trials in the future. In addition, it enables the development of peer-to-peer and mentoring relationships to enhance future career development.

80 students are selected using a competitive application process that consists of a protocol concept, personal statement, and support from an existing mentor. Those accepted to the Workshop will have access to world-renowned faculty members who, through the course of the Workshop, will help students develop concept sheets into IRB-ready clinical trials, ready for submission at their own institutions.
WHY DO WE NEED THIS WORKSHOP?

The Workshop trains early-career investigators how to design and conduct cancer clinical trials that produce definitive results. Its primary goal is to assure that new therapeutic and preventive treatments are tested in the clinic in a robust and efficient way. Training, mentoring, and retaining clinical cancer investigators benefits public health by efficiently testing treatments that can be readily made available to cancer patients, improving their quality of life and survival.

KEY BENEFITS FOR ATTENDEES

- Exclusive access to and mentoring by up to 40 highly experienced clinical experts in the field of oncology from Europe and North America
- Exceptional opportunity to meet and network with an elite group of up to 80 junior clinical oncologists from all over the world
- Outstanding educational experience in a unique setting conducive to professional relationship building, learning and development
- Access to a variety of educational tools designed to enable participants to develop their initial protocol proposal into a complete protocol
- Establishment of a network for educational exchanges between early career clinicians worldwide

WORKSHOP DIRECTORS

Saskia Litiere  
EORTC Headquarters, Brussels, Belgium

Emiliano Calvo  
START Madrid – Centro Integral Oncológico Clara Campal, Madrid, Spain

Lee M. Ellis  
The University of Texas – MD Anderson Cancer Center, Houston, USA
2. EDUCATION FORMAT

The Scientific Sessions have been specially structured to cater to all learning needs and will use one of the formats:

**Protocol Development Group Sessions**

These sessions form the core activity of this Workshop and allow students to complete the writing of their protocol by applying the knowledge acquired during the Workshop. Students will receive extensive feedback on their trial concepts from designated faculty within assigned groups comprising a maximum of ten students.

**Meet your Expert Sessions**

One-to-one sessions where students will have access to experts providing individual counselling and advice on protocol related issues and advice on career development.

**Small Group Discussion Sessions**

Sessions that focus on topics that are essential to the success of clinical trials and facilitating discussion on and around the difficulties and challenges of a particular type of trial. Attendance to these sessions is limited to maximise interaction and information exchange.

**Lectures and Panel Discussions**

Presentations by key experts on specific topics will provide participants with an overview of the design and implementation of high-quality clinical trials. This will be followed by a panel discussion during which Faculty and students can explore issues raised during the talks in greater depth.
3. FACTS & FIGURES

Applicants versus the number of Students Accepted (1999-2019)

Geographical Distribution of Applicants vs Accepted Fellows (1999-2019)

North America: 259 / 179
Latin America & Caribbean: 91 / 37
Europe: 1,905 / 1,277
Eastern and Central Europe & Central Asia: 289 / 83
North Africa & Middle East: 104 / 40
Africa: 17 / 4
Asia Pacific: 95 / 52

Participants by Oncology Specialty 2019
- Medical Oncology 70%
- Clinical Oncology 8%
- Paediatric Oncology 8%
- Radiation Oncology 5%
- Thoracic Oncology 4%
- Genitourinary Oncology 1%
- Gynaecology 1%
- Nuclear Medicine 1%
- Supportive Care 1%
- Surgical Oncology 1%

Participants by Gender 2019
- Female 67%
- Male 33%
3. FACTS & FIGURES

Protocols by Phase

Protocols ranged from Phase 1 to phase III with 56% being phase II trials.

![Pie chart showing protocols by phase]

Tumour type of protocols to be developed in 2019 Workshop

<table>
<thead>
<tr>
<th>Tumour Type</th>
<th>Total</th>
<th>Tumour Type</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast Cancer</td>
<td>12</td>
<td>Ovarian Cancer</td>
<td>2</td>
</tr>
<tr>
<td>Solid Tumours</td>
<td>6</td>
<td>Pleural Mesothelioma</td>
<td>2</td>
</tr>
<tr>
<td>Prostate Cancer</td>
<td>6</td>
<td>Sarcoma</td>
<td>2</td>
</tr>
<tr>
<td>Pancreatic Cancer</td>
<td>5</td>
<td>Urothelial Carcinoma</td>
<td>2</td>
</tr>
<tr>
<td>Renal cell Carcinoma</td>
<td>5</td>
<td>Acute Myeloid Lymphoma</td>
<td>1</td>
</tr>
<tr>
<td>Colorectal Cancer</td>
<td>4</td>
<td>Adenocarcinomas</td>
<td>1</td>
</tr>
<tr>
<td>Gastric Cancer</td>
<td>4</td>
<td>Cutaneous T-Cell Lymphoma</td>
<td>1</td>
</tr>
<tr>
<td>Head and Neck Cancer</td>
<td>4</td>
<td>Germ Cell Tumour</td>
<td>1</td>
</tr>
<tr>
<td>Neuroblastoma</td>
<td>3</td>
<td>Glioblastoma Multiforme</td>
<td>1</td>
</tr>
<tr>
<td>Bladder Cancer</td>
<td>2</td>
<td>Gynaecological Cancer</td>
<td>1</td>
</tr>
<tr>
<td>Cervical Cancer</td>
<td>2</td>
<td>Hodgkin’s Lymphoma</td>
<td>1</td>
</tr>
<tr>
<td>Hepatocellular Carcinoma</td>
<td>2</td>
<td>Lung Adenocarcinoma</td>
<td>1</td>
</tr>
<tr>
<td>Melanoma</td>
<td>2</td>
<td>Non Hodgkin Lymphoma</td>
<td>1</td>
</tr>
<tr>
<td>Neuroendocrine</td>
<td>2</td>
<td>Oesophageal Cancer</td>
<td>1</td>
</tr>
<tr>
<td>Non Small lung Cancer</td>
<td>2</td>
<td>Salivary Gland Cancer</td>
<td>1</td>
</tr>
</tbody>
</table>
4. CORPORATE SUPPORT OPPORTUNITIES

Our corporate sponsorship opportunities will strategically support your corporate social responsibility goals. They offer a great opportunity for your company to show its involvement in an educational programme that will ultimately contribute to better research and improved public health worldwide.

<table>
<thead>
<tr>
<th></th>
<th>Diamond¹</th>
<th>Gold</th>
<th>Silver</th>
<th>Bronze</th>
<th>Contributor</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>€ 95,000</td>
<td>€ 55,000</td>
<td>€ 37,500</td>
<td>€ 25,000</td>
<td>€ 10,000</td>
</tr>
</tbody>
</table>

| Number of corporate delegates¹ | 2 | 1 | 0 | 0 | 0 |
| On-site company name recognition on all message screens | ✓ | ✓ | ✓ | ✓ | ✓ |
| Company name and logo on acknowledgement leaflet distributed on-site | ✓ | ✓ | ✓ | ✓ | ✓ |
| On-site company acknowledgement in the Industry Corner | ✓ | ✓ | ✓ | ✓ | ✓ |
| Statement at the Welcome Session of the Workshop | ✓ | ✓ | ✓ | ✓ | ✓ |
| Company name included on all Workshop platforms | ✓ | ✓ | ✓ | ✓ | ✓ |
| Bag insert¹ | ✓ | ✓ | | | |
| Observer pass for one day | ✓ | ✓ | ✓ | | |
| Banner ad targeting the MCCR Workshop database post event. | | | | | |
| Company name & logo printed on the delegate bag | | | | | |
| Supporter’s logo on the Workshop website links to the supporter’s corporate website | | | | | |
| Supporter’s logo on the Workshop website links to the supporter’s corporate website | | | | | |

¹ This level of support is available to companies who commit to support the MCCR Workshop for three consecutive years. If the sponsor does not confirm its re-engagement for the next edition during the defined period, its first right of choice will be revoked. This opportunity would then become available to another company.

² To participate in the Workshop, candidates must fulfill the following Corporate Delegate Criteria.
- The candidate must be a physician specialising in oncology and submit the following items by the 10 April 2020:
  - Personal details and contact information;
  - One-page description of the clinical therapeutic trial protocol to be written during the Workshop;
  - Statement of motivation outlining the reasons for wanting to participate in this workshop.
- Travel and accommodation will not be covered by MCCR Workshop.

5. BOOKING FORM

MCCR Workshop 2020 Corporate Sponsorship Booking Form

Organisation: ____________________________________________
Contact Person: __________________________________________
Company VAT number: ______________________________________
Purchase order number: _____________________________________
Address: __________________________________________________________________________
Zip/Postal Code: __________________ City: ____________________________
Country: ______________________________________________________
Telephone: ______________________ Fax: __________________________
E-mail: _______________________________________________________

We would like to support the 20th Workshop on Methods in Clinical Cancer Research as:

☐ Diamond Sponsor 4 € 95 000 5
☐ Gold Sponsor € 55 000 5
☐ Silver Sponsor € 37 500 5
☐ Bronze Sponsor € 25 000 5
☐ Contributor € 10 000 5

We agree to pay the total cost of the selected Corporate Sponsorship 30 days from the date on the invoice.
We accept the sponsorship packages as described in the Corporate Support Prospectus 2019 and agree to observe and to be bound by them.

Date: __________________ Signature: ____________________________

Please complete and return to the MCCR Workshop Secretariat, c/o EORTC, Avenue E. Mounier 83, B-1200 Brussels, or E-mail to: rik.bollaert@eortc.org

Terms of Payment:

Invoices will be sent within two weeks following the confirmation. Payment is due within 30 days following the date of the invoice. Direct transfer payments should be made to the Workshop bank account: BE46 2100 5100 1036 (GEBABEBB), BNP Paribas Fortis, Rue Montagne du Parc, 3 (91616) 1000 Brussels, stating the number of the invoice. Sender’s bank charges are at the expense of the sponsor. The application is legally binding on the sponsor pending its acceptance in writing by the organiser. When applicable, sponsorship packages are subject to 21% VAT.

4 This level of support is available to companies who commit to support the MCCR Workshop for three consecutive years. If the sponsor does not confirm its re-engagement for the next edition during the defined period, its first right of choice will be revoked. This opportunity would then become available to another company.

5 Opportunities quoted are only valid and accepted in Euros
6. FELLOW TESTIMONIALS

“The MCCR Workshop gives you the essential tools, knowledge and guidance, that you would normally struggle to get in routine clinical training, to execute robust and meaningful clinical trials.”

Rebecca Hill, United Kingdom - Edition 20

“The workshop set-up was excellent. The objectives from the plenary sessions were key to improve clinical cancer research and engagingly presented. We could directly incorporate knowledge learned from the plenary sessions into our protocol. This ensures that newly acquired knowledge is immediately put into practice.”

Tessa Steenbruggen, Netherlands - Edition 21

“The MCCR Workshop was an excellent platform for learning, collaborating and meeting excellent mentors who are passionate about training fellows to do good research.”

Nagavalli Somasundaram, Singapore - Edition 20

“This was an outstanding experience that provided me with the great opportunity to develop a clinical trial protocol in just one week and at the same time learn the essentials of clinical trial design from world-renowned experts in the field.”

Stijn Keereweer, Netherlands - Edition 20

“The MCCR Workshop provides an invaluable and rare opportunity to receive close guidance from world-class mentors and sage, experienced statisticians – all of whom were generous with their time and experience.”

Aly-Khan Lalani, USA - Edition 19

“This is a very good opportunity for young oncologists to get a deep understanding of protocol development and acquire new insights from the experts.”

Christine Schumacher from Roche, Switzerland - Edition 19
22ND EDITION MCCR WORKSHOP
METHODS IN CLINICAL CANCER RESEARCH

Contact Us
MCCR Workshop Secretariat
EORTC
Avenue E. Mounier 83
B-1200 Brussels, Belgium
Tel: +32 2 774 15 13
E-mail: mccr@eortc.org

Corporate Sponsorship Opportunities
Rik Bollaert,
EORTC Corporate Relations Consultant
E-mail: rik.bollaert@eortc.org
Tel: +33 645 244 442

SINT-MICHELSTEDT NETHERLANDS
26 JUNE > 2 JULY 2020

eortc.org/mccr